Methods using eosinophil-specific apoptosis inducer
AssigneeKyowa Hakko Kogyo Co., Ltd.
InventorsEmi Hosaka, Kazuyasu Nakamura, Masamichi Koike, Kenya Shitara, Nobuo Hanai
Life of this patent
Estimating the term…
Abstract
The present invention provides an apoptosis inducer and a therapeutic agent for eosinophilic diseases which comprises, as an active ingredient, an antibody which reacts specifically with eosinophils and induces apoptosis of eosinophils; and a method for inducing eosinophil apoptosis using the antibody, and a method for specifically reducing or removing eosinophils in peripheral blood or tissues using the antibody.
Claims12
A method for specifically inducing apoptosis of an eosinophil, comprising:
- administering an anti-human interleukin-5 receptor α-chain monoclonal antibody with an Fc region of the human IgG1 subclass that has antibody-dependent cellular cytotoxicity to a patient in need thereof in an amount effective to induce apoptosis of an eosinophil in said patient.
A method for specifically reducing or removing eosinophils in peripheral blood or in tissues infiltrated with eosinophils, compnsing:
- administering an anti-human interleukin-5 receptor α-chain monoclonal antibody with an Fc region of the human IgG1 subclass that has antibody-dependent cellular cytotoxicity to a patient in need thereof in an amount effective to remove or reduce said eosinophils.
Dependencies are inferred from the claim text.